The FDA has refused to approve Novaral's siRNA drug inclisiran

Hyperlipidemia refers to abnormally elevated lipoproteins in the blood.
main components of blood lipids are cholesterol, triglycerides and phospholipids.
Pharmaceuticals said Friday that the FDA has issued a full response letter (CRL) to its marketing application for inclisiran, a siRNA drug for PCSK9, which is expected to be used to treat hyperlipidemia in adults with elevated LDL-cholesterol.
the Swiss drugmaker noted that the FDA had not raised any concerns about the efficacy or safety of inclisiran, but that there were still unresolved facility issues.
the drug, which was launched in Europe earlier this month, is used to treat primary hypercholesterolemia or mixed lipid abnormalities.
this decision is based on the results of the ORION Clinical Development Program, including the Phase III ORION-9 study, the ORION-10 study, and the ORION-11 study, which showed that inclisiran was able to effectively and consistently reduce LDL-cholesterol (up to 52%).
said it would communicate the FDA's questions to European manufacturing plants within 10 business days.
。